Insights Into the Management of Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Perspectives of community physicians from across the US on current practices in the management of LR-MDS

California – October 12, 2024
Purchase Report

Faculty Chair

Danko Martincic, MD

Beacon Clinic, Coeur d'Alene, ID, USA

More Information

  • San Diego, CA
  • California, Wisconsin, Illinois, Missouri, Tennessee

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on the experience with luspatercept in LR-MDS, including patient characteristics, management of cytopenias, and barriers to use
  • Disease state and data presentations were developed in conjunction with a national or regional oncology expert

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • The group of advisors comprised 10–15 medical oncologists representative of each region

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.